Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate ...
Arvinas, Inc. is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in New Haven, Connecticut. The company is a pioneer in targeted protein degradation, leveraging its proprietary PROTAC (Proteolysis Targeting Chimera) platform to develop novel therapies that selectively eliminate disease-causing proteins. Arvinas focuses on oncology, with lead candidates including Bavdegalutamide (ARV-110) for metastatic castration-resistant prostate cancer (mCRPC), ARV-471 (Vepdegestrant) for ER+/HER2- breast cancer, and ARV-766 for mCRPC. The company collaborates with major pharmaceutical partners such as Pfizer, Genentech, Roche, and Bayer. Financially, Arvinas has a market cap of approximately $564 million (as of latest data) and is investing heavily in R&D, with R&D expenses accounting for about 75% of revenue. The company employs 246 people and has a strong balance sheet with a current ratio of 7.9, indicating ample liquidity. Under the leadership of CEO Randy Teel and founder Dr. Craig Crews, Arvinas continues to advance its pipeline and expand its scientific capabilities. The company listed on NASDAQ in 2018 and remains committed to improving patient lives through innovative protein degradation medicines.
